Stage IV Inflammatory Breast Carcinoma

The clinicopathological features of inflammatory breast carcinoma (IBC), the effect of therapeutic options on survival outcome and the identification of prognostic factors were investigated in this study. Information on IBC patients were extracted from the Surveillance, Epidemiology, and End Results (SEER) database between 2010 and 2015. Cox proportional hazard regression was used to determine potential significant prognostic factors of IBC. A nomogram was then constructed to evaluate patient survival based on certain variables. Univariate and multivariate analyses revealed that race (p < 0.001), M stage (p < 0.001), surgery (p = 0.010), chemotherapy (CT) (p < 0.001), tumor size (p = 0.010), estrogen receptor (p < 0.001), progesterone receptor (p = 0.04), and human epidermal growth factor receptor 2 (p < 0.001) were all independent risk factors. The concordance index (C-index) of the nomogram was 0.735, which showed good predictive efficiency. Survival analysis indicated that IBC patients without CT had poorer survival than those with CT (p < 0.001). Stratified analyses showed that modified radical mastectomy (MRM) had significant survival advantages over non-MRM in patients with stage IV IBC (p = 0.031). Patients treated with or without CT stratified by stage III and stage IV showed better survival than those without stage III and IV (p < 0.001). Trimodality therapy resulted in better survival than surgery combined with CT or CT alone (p < 0.001). Competing risk analysis also showed the same results. The nomogram was effectively applied to predict the 1, 3 and 5-year survival of IBC. Our nomogram showed relatively good accuracy with a C-index of 0.735 and is a visualized individually predictive tool for prognosis. Treatment strategy greatly affected the survival of patients. Trimodality therapy was the preferable therapeutic strategy for IBC. Further prospective studies are needed to validate these findings.

Download Full-text

Delayed presentation of inflammatory breast carcinoma during the COVID-19 pandemic

European Surgery ◽

10.1007/s10353-021-00726-8 ◽

2021 ◽

Author(s):

Daniele Bernardi ◽

Emanuele Asti ◽

Giulia Bonavina ◽

Alberto Luporini ◽

Claudio Clemente ◽

...

Keyword(s):

Breast Carcinoma ◽

Delayed Presentation ◽

Inflammatory Breast Carcinoma

Download Full-text

Wnt (canonical and non canonical) pathways in breast carcinoma with extensive vascular invasion and inflammatory breast carcinoma

Pathology - Research and Practice ◽

10.1016/j.prp.2021.153347 ◽

2021 ◽

Vol 219 ◽

pp. 153347

Author(s):

A. Remo ◽

S. Sina ◽

S. Barbi ◽

I. Simeone ◽

J. Insolda ◽

...

Keyword(s):

Breast Carcinoma ◽

Vascular Invasion ◽

Inflammatory Breast Carcinoma ◽

Canonical Pathways

Download Full-text

Abstract PS19-07: Plasma exosomal miRNAs: A minimally invasive diagnostic biomarker for inflammatory breast carcinoma

10.1158/1538-7445.sabcs20-ps19-07 ◽

2021 ◽

Author(s):

Sarah Hamdy Ahmed ◽

Ahmed El-Damen ◽

Mohamed A. Badawy ◽

Mohamed El-Shinawi ◽

Martin Götte ◽

...

Keyword(s):

Breast Carcinoma ◽

Minimally Invasive ◽

Diagnostic Biomarker ◽

Inflammatory Breast Carcinoma ◽

Exosomal Mirnas

Download Full-text

Survey of UK practice for management of breast cancer metastases to the neck

Annals of The Royal College of Surgeons of England ◽

10.1308/003588412x13171221591736 ◽

2012 ◽

Vol 94 (7) ◽

pp. 484-489 ◽

Cited By ~ 7

Author(s):

B Bisase ◽

C Kerawala

Keyword(s):

Breast Cancer ◽

Breast Carcinoma ◽

Head And Neck ◽

Neck Dissection ◽

Current Practice ◽

Stage Iv ◽

Evidence Base ◽

Cervical Metastases ◽

Stage Iv Disease ◽

The Uk

INTRODUCTION Cervical metastases from breast carcinoma are rare and their management is controversial. Between 1987 and 2002 the American Joint Committee on Cancer (AJCC) staged patients with supraclavicular fossa nodal disease as M1 but the subsequent demonstration that patients with regional stage IV disease had better outcomes than visceral stage IV disease led to a reclassification of the former to stage IIIC in 2003. The literature remains inconsistent regarding the fate of these patients. Despite the attendant morbidity of treatment and lack of knowledge regarding long-term survival, we hypothesised that current practice varies in the UK and a unified approach does not exist. The aim of this study was therefore to determine current practice and opinion of both head and neck specialists and breast cancer clinicians in the UK. METHODS Questionnaires were disseminated to 185 head and neck surgeons, breast surgeons and their oncology counterparts. These outlined a clinical scenario of a patient with a history of T3 primary breast cancer presenting with cervical and supraclavicular nodal metastases, with opinion being sought regarding the significance of this status and the individual’s practical approach to the problem. The extent of any proposed neck dissection was also explored. RESULTS Of the 117 respondents, a noticeable variation in opinion was evident. Contrary to the current AJCC staging, 61% of clinicians felt that both level V and III metastases represented stage IV disease. There was a tendency towards aggressive surgical treatment with a third recommending comprehensive neck dissection despite a lack of evidence base. A disparity was noted between adjuvant treatments offered and the final pN stage. CONCLUSIONS This study suggests that at present there is widespread inconsistency in the management of breast carcinoma cervical metastases in the UK. There is a need to unify practice with an evidence base in order to improve informed multidisciplinary decision making and, ultimately, patient care. This study goes some way to supporting multicentre collaboration in order to achieve that aim.

Download Full-text